HealthTree Logo HealthTree Foundation
Donate

Notifications

You're all caught up

HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results | Paul Richardson, MD | ASH 2023

Posted by
HealthTree Logo HealthTree
• December 28, 2023

Description

Paul Richardson presetns Mezigdomide Plus Dexamethasone in RRMM: CC-92480-MM-002 Trial Results at ASH 2023.

On this video

Healthtree contact Paul Richardson, MD, Specialist

Paul Richardson, MD, Specialist

Dana Farber Cancer Institute

Related Content

  • Video The CELMoD, Mezigdomide, Shows Dramatic Results in Relapsed Myeloma | Paul Richardson, MD | #IMS25
  • Video Promising Result from a Novel Mezigdomide Combination Trial | Fredrik Schjesvold, MD, PhD | #EHA2025
  • Video New Myeloma Combinations Using CELMoD’s and Antibody Drug Conjugates | Paul Richardson, MD | #ASH24
  • Video Preliminary Results of Mezigdomide Combinations in RRMM Patients | Luciano Costa, MD, PhD | IMS 2024
  • Video Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 Trial | Luciano Costa, MD | EHA 2024
  • Video SUCCESSOR-2 Trial: Mezigdomide Triplet Shows Powerful Results in Relapse/Refractory Multiple Myeloma